8-methoxy-1H-[1]benzazepine-2,5-(3H,4H)-dione | 498557-37-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 8-methoxy-1H-[1]benzazepine-2,5-(3H,4H)-dione
• 英文别名: 8-methoxy-3,4-dihydro-1H-[1]benzazepin-2,5-dione；8-methoxy-3,4-dihydro-1H-benzo[b]azepine-2,5-dione；8-methoxy-3,4-dihydro-1H-1-benzazepine-2,5-dione
• CAS: 498557-37-2
• 化学式: C₁₁H₁₁NO₃
• 分子量: 205.213
• InChiKey: YAJACGIYSXZKKD-UHFFFAOYSA-N

物化性质

• 沸点：
  439.9±45.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-methoxy-1H-[1]benzazepine-2,5-(3H,4H)-dione 在 四丁基溴化铵 、 三溴化硼 、 potassium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 1-(3-fluoro-4-methylbenzyl)-8-hydroxy-3,4-dihydro-1H-benzo[b]azepine-2,5-dione
  参考文献：
  名称：

  [EN] FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
  [FR] COMPOSÉS D'AZÉPINE FUSIONNÉS ET LEUR UTILISATION EN CANCÉROTHÉRAPIE

  摘要：

  本公开涵盖了许多内容，其中包括治疗或减轻癌症严重程度的化合物、制药组合物以及制备和使用这些化合物的方法。

  公开号：

  WO2022152097A1
• 作为产物：
  描述：

  8-甲氧基-1,3,4,5-四氢-苯并[B]氮杂革-2-酮 在 magnesium(II) nitrate 、 potassium permanganate 作用下， 以 水 、 叔丁醇 为溶剂， 反应 20.0h， 以44%的产率得到8-methoxy-1H-[1]benzazepine-2,5-(3H,4H)-dione
  参考文献：
  名称：

  Synthesis of Paullones with Aminoalkyl Side Chains

  摘要：

  Paullones 3 and 4 with aminoalkyl side chains in 2- or 3-position were synthesized as derivatives of kenpaullone 1. Both 3 and 4 showed the characteristic CDK1-inhibitory activity of the paullones and a modest antiproliferative activity on cultured human tumor cell lines. Hence, 3 and 4 appear to be suitable tools for affinity studies directed to find additional intracellular paullone targets.

  DOI：

  10.1002/1521-4184(200209)335:7<311::aid-ardp311>3.0.co;2-f

文献信息

• [EN] 5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZEPIN-6-THIONES AS PLK INHIBITORS<br/>[FR] 5, 7-DIHYDRO- 6H-PYRIMIDO [ 5, 4-D] [ 1 ] BENZAZÉPIN-6-THIONES UTILISÉES EN TANT QU'INHIBITEURS DE PLK
  申请人：MILLENNIUM PHARM INC

  公开号：WO2010065134A1

  公开（公告）日：2010-06-10

  This invention provides compounds of formula I: wherein R1, R2, R3, R4, R5, and R6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  本发明提供了公式I的化合物：其中R1、R2、R3、R4、R5和R6如说明书所述。这些化合物是PLK的抑制剂，因此可用于治疗增殖性、炎症性或心血管疾病。
• THIOLACTAMS AND USES THEREOF
  申请人：Bharathan Indu T.

  公开号：US20120302551A1

  公开（公告）日：2012-11-29

  This invention provides compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as described in the specification. The compounds are inhibitors of PLK and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  本发明提供了公式I的化合物：其中R1，R2，R3，R4，R5和R6如规范中所述。这些化合物是PLK的抑制剂，因此可用于治疗增生性、炎症性或心血管疾病。
• Evaluation and Comparison of 3D-QSAR CoMSIA Models for CDK1, CDK5, and GSK-3 Inhibition by Paullones
  作者：Conrad Kunick、Kathrin Lauenroth、Karen Wieking、Xu Xie、Christiane Schultz、Rick Gussio、Daniel Zaharevitz、Maryse Leost、Laurent Meijer、Alexander Weber、Flemming S. Jørgensen、Thomas Lemcke

  DOI：10.1021/jm0308904

  日期：2004.1.1

  With a view to the rational design of selective GSK-3beta inhibitors, 3D-QSAR CoMSIA models were developed for the inhibition of the three serine/threonine kinases CDK1/cyclin B, CDK5/p25, and GSK-3beta by compounds from the paullone inhibitor family. The models are based on the kinase inhibition data of 52 paullone entities, which were aligned by a docking routine into the ATP-binding cleft of a CDK1/cyclin B homology model. Variation of grid spacing and column filtering were used during the optimization of the models. The predictive ability of the models was shown by a leave-one-out cross-validation and the prediction of an independent set of test compounds, which were synthesized especially for this purpose. Besides paullones with the basic indolo [3,2-d] [1]benzazepine core, the test set comprised novel thieno [3',2':2,3]-azepino[4,5-b]indoles, pyrido[2',3':2,3]azepino[4,5-b]indoles, and a pyrido[3',2':4,5]pyrrolo[3,2-d] [1]benzazepine. The best statistical values for the CoMSIA were obtained for the CDK1-models (r(2) = 0.929 and q(2) = 0.699), which were clearly superior to the models for CDK5 (r(2) = 0.874 and q(2) = 0.652) and GSK-3 (r(2) = 0.871 and q(2) = 0.554).
• Identification of 2-Anilino-9-methoxy-5,7-dihydro-6<i>H</i>-pyrimido[5,4-<i>d</i>][1]benzazepin-6-ones as Dual PLK1/VEGF-R2 Kinase Inhibitor Chemotypes by Structure-Based Lead Generation
  作者：Anne-Marie Egert-Schmidt、Jan Dreher、Ute Dunkel、Simone Kohfeld、Lutz Preu、Holger Weber、Jan E. Ehlert、Bettina Mutschler、Frank Totzke、Christoph Schächtele、Michael H. G. Kubbutat、Knut Baumann、Conrad Kunick

  DOI：10.1021/jm901388c

  日期：2010.3.25

  To develop multikinase inhibitors with dual PLK1/VEGF-R2 inhibitory activity, the d-annulated 1-benzazepin-2-one scaffold present in the paullone family of kinase inhibitors was investigated as a general structure template suitable for anchoring annulated heterocycles at the hinge region of the ATP binding site. For this purpose, the indole substructure of the paullones was replaced by other nitrogen containing heteroaromatics. The designed scaffolds were synthesized and tested on the indicated kinases. The 2-anilino-5.7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones were found to be VEGF-R2 inhibitors with selectivity against the insulin receptor kinase. The attachment of a methoxy group to the 9-position of the scaffold led to additional PLK1 inhibitory activity, which was explained by an alternative binding mode of the 9-methoxy derivatives. Selected members of the compound class inhibited the VEGF-R2 autophosphorylation in human umbilical vein endothelial cells, the sprouting of human umbilical vein endothelial cell speroids, and the proliferation of diverse cancer cell lines.
• Darpones and water-soluble aminobutoxylated darpone derivatives are distinguished by matrix COMPARE analysis
  作者：Christian Prühs、Conrad Kunick

  DOI：10.1016/j.bmcl.2007.01.043

  日期：2007.4

  Darpones are a class of compounds with antiproliferative activity for cancer cells in vitro and in mouse models. In order to improve the solubility of the compounds, darpones with aminobutoxy side chains were synthesized. The new derivatives showed retained antiproliferative activity for cultured cancer cell lines. However, a change of the selectivity pattern in the in vitro cell line screening project of the American National Cancer Institute indicates that the solubilized derivatives might act through a different biological mechanism. A matrix COMPARE analysis of the cancer cell line screening data clearly distinguished darpones with and without solubilizing aminobutoxy side chains. (c) 2007 Elsevier Ltd. All rights reserved.